tutkimus Joukkueet - Stabilis 4.0

Viimeisin päivitys :
12/07/2025

tutkimus Joukkueet - Quality Evaluation Team, Samsung Bioepis Co

pdf

Japani

lääkelaboratorio

Quality Evaluation Team, Samsung Bioepis Co

Incheon

Email

sujin8171.park@samsung.com

Viitteet

Viitteet

(5)

1

In‑Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
Tak M, Jeong H, Yun J, Kim J, Kim S, Lee Y, Park S-J. (sujin8171.park@samsung.com)
Drugs R D - 2023 - ;23,4:363 - 375

2

Physicochemical and Biological Stability Assessment of SB11 (Ranibizumab Biosimilar) Under Ambient and In-Use Storage for Intravitreal Administration.
Kaiser P.K, Yun J, Kim S, Kim J, Park S.J. (sujin8171.park@samsung.com)
Ophtalmol Ther - 2023 - ; 12:985–998.

3

Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
Park D, Kim J, Yun J, Park S.J. (sujin8171.park@samsung.com)
Adv Ther - 2020 - ; 37: 4308–4324.

4

Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Yun J, Kim J, Chung J, Hwang S-J, Park S-J. (sujin8171.park@samsung.com)
Adv Ther - 2019 -

5

Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
Park D, Yun J, Hwang S-J, Park SJ. (sujin8171.park@samsung.com)
Adv Ther - 2019 - 36:442–450

Luettelo yhdisteistä

molekyylit tutkittu

(5)

		Adalimumab
		Bevacizumab
		Eculizumab
		Ranibizumab
		Trastuzumab

Mentions Légales

BESbswy